Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 435983, 13 pages
http://dx.doi.org/10.1155/2014/435983
Review Article

Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We Are and Where We Go

1Laboratori de Citogenètica Molecular, Servei de Patologia, Hospital del Mar, Passeig Marítim 25-29, 08003 Barcelona, Spain
2GRETNHE, Programa de Recerca en Càncer, Institut Hospital del Mar d’Investigacions Mèdiques, Doctor Aiguader 88, 08003 Barcelona, Spain
3Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Doctor Aiguader 88, 08003 Barcelona, Spain

Received 13 March 2014; Accepted 22 April 2014; Published 22 May 2014

Academic Editor: Ana Eugenia Rodríguez-Vicente

Copyright © 2014 Anna Puiggros et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Chromosomal abnormalities in chronic lymphocytic leukemia (CLL) are detected in up to 80% of patients. Among them, deletions of 11q, 13q, 17p, and trisomy 12 have a known prognostic value and play an important role in CLL pathogenesis and evolution, determining patients outcome and therapeutic strategies. Standard methods used to identify these genomic aberrations include both conventional G-banding cytogenetics (CGC) and fluorescence in situ hybridization (FISH). Although FISH analyses have been implemented as the gold standard, CGC allows the identification of chromosomal translocations and complex karyotypes, the latest associated with poor outcome. Genomic arrays have a higher resolution that allows the detection of cryptic abnormalities, although these have not been fully implemented in routine laboratories. In the last years, next generation sequencing (NGS) methods have identified a wide range of gene mutations (e.g., TP53, NOTCH1, SF3B1, and BIRC3) which have improved our knowledge about CLL development, allowing us to refine both the prognostic subgroups and better therapeutic strategies. Clonal evolution has also recently arisen as a key point in CLL, integrating cytogenetic alterations and mutations in a dynamic model that improve our understanding about its clinical course and relapse.